The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G).
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Takako Eguchi Nakajima
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Dainippon Sumitomo Pharma; Kyowa Hakko Kirin; Lilly Japan; Maruho; MERCK SERONO; MSD; Ono Pharmaceutical; Sanofi; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - A2 Healthcare; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Merck Serono; MSD K.K; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ichinosuke Hyodo
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Junki Mizusawa
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tomohiro Nishina
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Sakamoto
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Ono Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Lilly; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Katsunori Shinozaki
Honoraria - Asahi Kasei; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD K.K; Ono Pharmaceutical; Pfizer; Sanofi; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hiroshi Katayama
Honoraria - Johnson & Johnson
 
Shinichiro Nakamura
No Relationships to Disclose